Please get together with your friends and short this.
It will help to make more stock available to investors.
But before you do, take another look at the chart and note the daily volumes.
See anything different vis-a-vis last year, Mr. Chart Reader?
One should know something about what one invests in.
So let's presume for a moment that you have some scientific training and or are otherwise able to understand the science results of this science company.
Now tell me if there have been any significant developments since last year or is this merely a cyclical industrial company in your mind?
But alas, that may be a tall order for the average product of US public education where only 7% reached advanced level in eighth grade math (NY Times).
It may thus be necessary to spell it out for you in big type and bright highlight that last year quarterly earnings would indeed be cause for concern with constant piecemeal stock offerings for survival.
You must do your homework here also to see if indeed there has been any change on that front.
I'm not saying that the stock market is completely efficient or there would be little opportunity due to mispricing.
But I can tell you that ARWR's late action has awakened and helped investors to understand the potential here.
At the present early single digit prices, the only thought they should have is to BUY.
Ok, now if you still find your argument superior, you must do your conviction and sell short.
But try to limit the stunt or you may never recover to benefit from the lesson.
This stock is heading for double digits, print this and put it on the wall.
my call is that the stock drops on quarterly earnings again
Then you're a complete idiot. Everybody knows quarterly earnings is a non-event at this point. The inflection points are clinical trials and potential partnerships right now. The stock went down last year at this time because they had just done a lousy placement. That is all history now, with enough cash for two years operation. You shouldn't short if you don't know the fundamentals.
what do you think they might discuss on the earnings call?? of course its about clinical trials and partnerships. so why did ARWR drop after they announced a partnership with Shire? And why did ARWR drop almost 30% after they secured funding on May 6th, to a low of 1.81-- the funding that you say will cover them for the next 2 years?? this stock has gone from 1.81 to 3.40 on fumes. I like the idea, I'm not short, but only a fool buys at these levels.